The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.